Search results for "Neoplastic"

showing 10 items of 2901 documents

Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents

2021

Three novel pyrazolo-[4,3-e][1,2,4]triazolopyrimidine derivatives (1, 2, and 3) were designed, synthesized, and evaluated for their in vitro biological activity. All three compounds exhibited different levels of cytotoxicity against cervical and breast cancer cell lines. However, compound 1 showed the best antiproliferative activity against all tested tumor cell lines, including HCC1937 and HeLa cells, which express high levels of wild-type epidermal growth factor receptor (EGFR). Western blot analyses demonstrated that compound 1 inhibited the activation of EGFR, protein kinase B (Akt), and extracellular signal-regulated kinase (Erk)1/2 in breast and cervical cancer cells at concentrations…

cervical cancercrystal X-ray analysisPharmaceutical ScienceAntineoplastic AgentsArticleAnalytical ChemistryHeLa03 medical and health sciencesbreast cancerQD241-4410302 clinical medicineDrug DiscoveryHumansEpidermal growth factor receptorPhysical and Theoretical Chemistrypyrazolo[124]triazolopyrimidineCytotoxicityProtein Kinase InhibitorsProtein kinase BCell Proliferation030304 developmental biologyMitogen-Activated Protein Kinase 1pyrazolo[124]triazolopyrimidine; EGF-receptor inhibitor; breast cancer; cervical cancer; molecular docking; crystal X-ray analysis0303 health sciencesBinding SitesMitogen-Activated Protein Kinase 3biologyChemistryKinaseOrganic ChemistryBiological activitymolecular dockingTriazolesbiology.organism_classificationMolecular biologyIn vitroErbB ReceptorsMolecular Docking SimulationPyrimidinesChemistry (miscellaneous)Docking (molecular)030220 oncology & carcinogenesisbiology.proteinMolecular MedicineProto-Oncogene Proteins c-aktEGF-receptor inhibitorHeLa CellsProtein BindingMolecules
researchProduct

Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-sp…

2012

Cetuximab is a human/mouse chimeric IgG1 monoclonal antibody (mAb) to epidermal growth factor receptor, approved for colorectal carcinoma treatment in combination with chemotherapy. The immune-mediated effects elicited by its human fraction of crystallization moiety might critically contribute to the overall anti-tumor effectiveness of the antibody. We therefore investigated cetuximab ability to promote colon cancer cell opsonization and phagocytosis by human dendritic cells (DCs) that are subsequently engaged in antigen-cross presentation to cytotoxic T-lymphocyte (CTL) precursors. Human colon cancer cell lines were evaluated for susceptibility to DC-mediated phagocytosis before and after …

cetuximab; chemotherapy; danger signal; cytotoxic-T-lymphocytes; phagocytosisCancer ResearchColorectal cancerSettore MED/06 - Oncologia MedicaAntigen-Presenting CellsAntibodies Monoclonal Humanizedchemotherapydanger signalCross-PrimingAntigenAntigens NeoplasmCell Line TumorAntineoplastic Combined Chemotherapy ProtocolscetuximabHumansMedicineCytotoxic T cellCetuximabbusiness.industrySettore BIO/14Antibodies MonoclonalphagocytosisDendritic CellsDendritic cellmedicine.diseasecytotoxic-T-lymphocytedigestive system diseasesTumor antigenCTL*OncologyColonic NeoplasmsCancer cellImmunologyLeukocytes MononuclearCancer researchbusinessHT29 Cellscytotoxic-T-lymphocytesT-Lymphocytes Cytotoxicmedicine.drug
researchProduct

Bleomycin, a selective inhibitor of DNA-dependent DNA polymerase from oncogenic RNA viruses.

1972

Abstract Bleomycin, an antibiotic, inhibits the DNA-dependent DNA polymerase from Rauscher murine leukemia virus. Higher concentrations of BLM ∗ are required to inhibit it's RNA-dependent DNA polymerase. These inhibition effects of the non-competitive type are not altered by preincubation of the DNA with BLM. Under comparable conditions neither the DNA-dependent DNA polymerase activity from E. coli and mouse liver nor the DNA-dependent RNA polymerase activity from mouse lymphoma cells are affected by BLM.

congenital hereditary and neonatal diseases and abnormalitiesTime FactorsLymphomaDNA polymeraseHepatitis B virus DNA polymeraseUracil NucleotidesDNA polymerase IIBiophysicsRNA-dependent RNA polymeraseCytosine NucleotidesTritiumBiochemistryRauscher VirusCell LineBleomycinMiceEscherichia coliAnimalsMolecular BiologyPolymeraseDNA clampAntibiotics Antineoplasticbiologyurogenital systemnutritional and metabolic diseasesCell BiologyDNAMolecular biologyReverse transcriptaseKineticsReal-time polymerase chain reactionLiverDNA Nucleotidyltransferasesbiology.proteinRNABiochemical and biophysical research communications
researchProduct

Bleomycin: Action on growth of oncogenic RNA viruses and on cell transformation

1975

Bleomycin (BLM) inhibits cell proliferation of noninfected chick embryo fibroblasts by blocking their DNA synthesis selectively. Chick embryo fibroblasts have beentransformed by Schmidt-Ruppin D strain of Rous Sarcoma Virus. Transformation has been determined by a focus assay. Foci formation is strongly reduced by BLM. Virus replication is inhibited by BLM in growing and confluent monolayer cells. This result might be explained by the observation that this drug reduces proliferation of growing and of confluent monolayer cells very sensitively. During the first 24 hours after infection the BLM inhibitory effect is more pronounced than in the case of BLM-application during the period 24--48 h…

congenital hereditary and neonatal diseases and abnormalitiesTime Factorsanimal structuresTranscription GeneticCell divisionCellChick EmbryoBiologyVirus ReplicationVirusBleomycinTranscription (biology)VirologymedicineAnimalsRNA VirusesCells CulturedRous sarcoma virusurogenital systemCell growthnutritional and metabolic diseasesRNADNAGeneral MedicineFibroblastsbiology.organism_classificationVirologyMolecular biologyCell Transformation Neoplasticmedicine.anatomical_structureAvian Sarcoma VirusesViral replicationembryonic structuresRNARNA ViralArchives of Virology
researchProduct

WRN protects against topo I but not topo II inhibitors by preventing DNA break formation

2008

The Werner syndrome helicase/3′-exonuclease (WRN) is a major component of the DNA repair and replication machinery. To analyze whether WRN is involved in the repair of topoisomerase-induced DNA damage we utilized U2-OS cells, in which WRN is stably down-regulated (wrn-kd), and the corresponding wild-type cells (wrn-wt). We show that cells not expressing WRN are hypersensitive to the toxic effect of the topoisomerase I inhibitor topotecan, but not to the topoisomerase II inhibitor etoposide. This was shown by mass survival assays, colony formation and induction of apoptosis. Upon topotecan treatment WRN deficient cells showed enhanced DNA replication inhibition and S-phase arrest, whereas af…

congenital hereditary and neonatal diseases and abnormalitiesWerner Syndrome HelicaseDNA RepairCell SurvivalDNA damageDNA repairBlotting WesternApoptosisBone NeoplasmsBiologyTopoisomerase-I InhibitorBiochemistryArticleWerner Syndrome HelicaseColony-Forming Units AssayHistonesTumor Cells CulturedmedicineHumansTopoisomerase II InhibitorsEnzyme InhibitorsRNA Small InterferingeducationMolecular BiologyEtoposideOsteosarcomaeducation.field_of_studyRecQ HelicasesTopoisomeraseCell CycleDNA Breaksnutritional and metabolic diseasesCell BiologyAntineoplastic Agents PhytogenicMolecular biologyDNA Topoisomerases Type IIExodeoxyribonucleasesBromodeoxyuridineDNA Topoisomerases Type IDNA Replication InhibitionCancer researchbiology.proteinTopoisomerase I InhibitorsTopoisomerase-II InhibitorTopotecanCamptothecinmedicine.drugDNA Repair
researchProduct

Targeting DNA double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment

2016

// Bregje van Oorschot 1 , Giovanna Granata 1 , Simone Di Franco 2 , Rosemarie ten Cate 1 , Hans M. Rodermond 1 , Matilde Todaro 3 , Jan Paul Medema 1 , Nicolaas A.P. Franken 1 1 Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine, Department of Radiation Oncology, Academic Medical Center, Cancer Genomics Center, Amsterdam, The Netherlands 2 Department of Surgical, Oncological and Stomatological Sciences (DICHIRONS), Cellular and Molecular Pathophysiology Laboratory, University of Palermo, Palermo, Italy 3 Biomedical Department of Internal and Specialistic Medicine (DIBIMIS), University of Palermo, Palermo, Italy Correspondence to: Nicol…

double-strand break0301 basic medicineRadiation-Sensitizing AgentsPathologymedicine.medical_specialtyDNA End-Joining RepairRadiobiologyDNA repairDNA damageMorpholinesmedicine.medical_treatmentMice NudeUterine Cervical NeoplasmsDNA repairBreast NeoplasmsDNA-Activated Protein KinaseRadiation ToleranceMice03 medical and health sciences0302 clinical medicineCancer stem cellTumor Cells CulturedAnimalsHumansMedicineDNA Breaks Double-StrandedHomologous RecombinationDNA-PKcsdouble-strand breaksRadiotherapybusiness.industryCancerradiation oncologyHyperthermia Inducedhyperthermiamedicine.diseaseRadiation therapyradiation oncology.030104 developmental biologyOncologyChromones030220 oncology & carcinogenesisCancer cellNeoplastic Stem CellsCancer researchFemalebusinessResearch PaperDNA DamageOncotarget
researchProduct

Gas phase behavior of radical cations of perfluoroalkyl-1,2,4-triazines: an experimental and theoretical study

2009

Electron ionization mass spectrometry and low-energy collision-induced decomposition reactions occurring in a tridimensional ion trap, together with density functional theory (DFT) calculations on neutrals, even- and odd-electron cations, have been used to study the gas-phase ion chemistry of a series of perfluoroalkyl-1,2,4-triazines. Loss of oxygen, due to thermal degradation occurring before ionization, likely involving the hydroxylamino group, has been observed. Compounds having a carbonyl group at position 6 of the triazine ring fragment in the source by elimination of NO followed by HF or CO. The decomposition pathways occurring due to CID experiments have shown interesting features d…

electron ionizationFree RadicalsStereochemistryIonic bondingDFT calculationAntineoplastic AgentsMass spectrometryGas Chromatography-Mass SpectrometryIonradical ionTandem Mass SpectrometryComputational chemistrySpectroscopyElectron ionizationFluorocarbonsMolecular StructureTriazinesChemistryPolyatomic ionSettore CHIM/06 - Chimica OrganicaModels ChemicalRadical ionUnpaired electronDensity functional theorytriazineGasesfluorinated compounds
researchProduct

Correlative Raman-Electron-Light (CREL) Microscopy Analysis of Lipid Droplets in Melanoma Cancer Stem Cells.

2022

Among all neoplasms, melanoma is characterized by a very high percentage of cancer stem cells (CSCs). Several markers have been proposed for their identification, and lipid droplets (LDs) are among them. Different techniques are used for their characterization such as mass spectrometry, imaging techniques, and vibrational spectroscopies. Some emerging experimental approaches for the study of LDs are represented by correlative light–electron microscopy and by correlative Raman imaging–scanning electron microscopy (SEM). Based on these scientific approaches, we developed a novel methodology (CREL) by combining Raman micro-spectroscopy, confocal fluorescence microscopy, and SEM coupled with an…

electron microscopyClinical BiochemistrySettore MED/50 - Scienze Tecniche Mediche ApplicateBiomedical Engineeringmelanoma cancer stem cellRaman micro-imaginglipid dropletElectronsGeneral MedicineLipid DropletsSpectrum Analysis RamanAnalytical Chemistrycorrelative microscopy; lipid droplets; melanoma cancer stem cells; Raman micro-imaging; electron microscopyMicroscopy Electron ScanningNeoplastic Stem CellsHumanscorrelative microscopySettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioInstrumentationEngineering (miscellaneous)MelanomaBiotechnologyBiosensors
researchProduct

Annexin-1 downregulation in thyroid cancer correlates to the degree of tumour differentiation

2006

We investigated the expression of annexin-1 (ANXA1) in thyroid carcinoma cell lines and in thyroid cancers with a different degree of differentiation. The highest level of ANXA1 expression examined by Western blotting was detected in the papillary carcinoma cells (NPA) and in the follicular cells (WRO). On the other hand, the most undifferentiated thyroid carcinoma cells (ARO and FRO) presented the lowest level of ANXA1 expression. In surgical tissue specimens from 32 patients with thyroid cancers, we found high immunoreactivity for ANXA1 in papillary (PTC) and follicular (FTC) thyroid cancers while in undifferentiated thyroid cancers (UTC) the expression of the protein was barely detectabl…

endocrine systemCancer ResearchPathologymedicine.medical_specialtyannexin-1endocrine system diseasesCellular differentiationThyroid Glandmedicine.disease_causeThyroid carcinomaDownregulation and upregulationannexinopathieTumor Cells CulturedmedicineHumansThyroid Neoplasmsdifferentiation markerThyroid cancerThyroid NeoplasmAnnexin A1PharmacologyRegulation of gene expressionbusiness.industryThyroidCell Differentiationmedicine.diseaseapoptosithyroid carcinomaGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyCell cultureMolecular MedicineCarcinogenesisbusinessHumanCancer Biology & Therapy
researchProduct

RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development

2012

The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ERα) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ERα levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive gen…

endocrine systemCancer Researchmedicine.medical_specialtyCell SurvivalGene ExpressionEstrogen receptorApoptosisBreast NeoplasmsCell Cycle ProteinsMice SCIDBiologyMiceBreast cancerDownregulation and upregulationMice Inbred NODInternal medicineGeneticsmedicineAnimalsHumansFulvestrantMolecular BiologyCellular SenescenceCell ProliferationRegulation of gene expressionEstradiolFulvestrantTumor Suppressor ProteinsEstrogen AntagonistsEstrogen Receptor alphaCancerEstrogensCell Cycle Checkpointsmedicine.diseaseGene Expression Regulation NeoplasticEndocrinologyProteolysisMCF-7 CellsCancer researchFemaleEctopic expressionEstrogen receptor alphaNeoplasm TransplantationSignal Transductionmedicine.drugOncogene
researchProduct